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Acquired Hepatocerebral Degeneration in the Absence 
of Portosystemic Shunting
Dear Editor, 
Acquired hepatocerebral degeneration (AHD) is a neurological disorder caused by chron-
ic liver diseases associated with portosystemic shunting. It manifests clinically with cogni-
tive impairment and movement disorders. T1-weighted magnetic resonance imaging (MRI) 
typically shows bilateral pallidal hyperintensities.1 
A 57-year-old hypertensive man was admitted with a 2-month history of subacute and 
progressive parkinsonian syndrome. He reported an alcohol intake of 40 grams per day. The 
findings of a general physical examination were normal. A neurological examination showed 
facial hypomimia, global bradykinesia, symmetrical extrapyramidal rigidity with bilateral 
hand resting tremor, and slowed finger-tap movements; his motor score on part 3 of the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) was 32/108. Neuropsychological tests dis-
closed attention deficit, constructive apraxia, and a Mini Mental State Examination score of 
23/30. Laboratory tests showed very mild hyperbilirubinemia (1.3 mg/dL), hypoalbumin-
emia (3.4 g/dL), and thrombocytopenia (140×103/μL). Serum ammonia levels were tested 
twice, with conflicting results: initially 93 μmol/L, and 28 μmol/L 2 days later. The prothrom-
bin-time international normalized ratio was 1.32. Serum copper, ceruloplasmin, and urinary 
copper excretion were all within the normal ranges. Serum gamma glutamyl transpeptidase 
was 213 U/L (normal range=3–50 U/L), glutamate oxaloacetate transaminase was 67 U/L 
(normal range=1–31 U/L) and glutamate pyruvate transaminase 53 U/L (normal range=1–31 
U/L). Liver elastography showed stiffness compatible with parenchymal fibrosis. A slit-lamp 
examination did not reveal any Kayser-Fleischer rings. An abdominal ultrasound scan showed 
evidence of chronic parenchymal liver disease and a normal portal vein diameter (11.5 mm), 
with the absence of splenomegaly, collateral splenorenal hematic circles, and umbilical vein 
recanalization. Ultrasound portal flowmetry disclosed a regular hepatopetal flow. Gastros-
copy findings were normal. 
A diagnosis of alcoholic hepatic cirrhosis was made, with a Child-Pugh classification of 
A6. Brain MRI showed a slight bilateral globus pallidus hyperintensity in T1-weighted axial 
images and a venous developmental abnormality in the left frontal lobe as a collateral find-
ing (Fig. 1). The patient was started on levodopa therapy (150 mg/daily), and alcohol intake 
was stopped. The findings of laboratory examinations 6 months later were almost normal, 
and the patient’s neurological status had greatly improved (UPDRS part 3 score=6/108). Le-
vodopa therapy was continued. The patient refused a second MRI scan. 
The present case is unusual due to the presentation of AHD as a consequence of chronic 
liver disease without clinical or ultrasonographic evidence of a portosystemic shunt. To our 
knowledge, no similar cases have been reported in the literature. We are aware that ultrasound 
is not the gold-standard test for identifying a portosystemic shunt. However, we feel confident 
that the results from the ultrasound scans and portal flowmetry in our patient were sufficient-
ly reliable to represent no evidence of shunting. The pathogenesis of AHD in patients with-
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out clear evidence of portosystemic shunting remains un-
clear, since portosystemic shunting seems to play a crucial 
role in the development of AHD. This allows the toxins am-
monia, gamma aminobutyric acid, and aromatic amino acids 
to bypass the first-pass elimination by the liver and thereby 
accumulate in the brain.1 As a consequence, the level of am-
monium and the conversion of glutamate into glutamine in-
crease in astrocytes, resulting in cell toxicity and an increased 
osmotic load with water accumulation.2 Manganese seems to 
be particularly involved in the onset of AHD, with convinc-
ing evidence that any pallidal MRI T1-weighted hyperinten-
sities are due to manganese accumulation.1 Manganese is a 
neurotoxic heavy metal that may induce glutamate-mediated 
excitotoxic injury with swelling of basal ganglia glial cells, 
cause oxidative stress, and impair dopaminergic neurotrans-
mission by altering postsynaptic D2 receptors.3
To explain why reversible AHD developed in the absence of 
a clear evidence of portosystemic shunt in our patient, we con-
jecture that pallidal manganese deposition started before the 
portosystemic shunt became clinically and radiologically evi-
dent. This is consistent with experimental animal models 
showing pallidal manganese accumulation in rats with chron-
ic liver disease without a portosystemic shunt.4 The pallidal 
manganese content was found to increase not only in portaca-
val-shunted rats but also in cirrhotic rats without a portosys-
temic shunt, underlying the possibility that liver failure alone 
can lead to manganese accumulation in the brain.4 Evidence 
for AHD developing in the absence of portosystemic shunt 
comes also from the patient reported by Aggarval et al.,5 who 
presented with reversible AHD during acute liver failure in the 
absence of cirrhosis. 
This case reports indicates that neurologists should consid-
er that AHD can develop in patients with chronic liver disease 
also in the absence of either clinical or instrumental evidence 
of portosystemic shunting. 
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Fig. 1. Moderate bilateral pallidus hyperintensities (arrows) in a T1-
weighted MRI image.
